|
|
Article: Study of molecular mechanisms of pro-apoptotic activity of NCX 4040, a novel nitric oxide-releasing aspirin, in colon cancer cell lines.(Research)
- Article from:
- Journal of Translational Medicine
- Article date:
- October 30, 2007
- Author:
CopyrightCOPYRIGHT 2007 BioMed Central Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Authors: Anna Tesei [1]; Marco Rosetti [1]; Paola Ulivi [1]; Francesco Fabbri [1]; Laura Medri [2]; Ivan Vannini [1]; Manlio Bolla [3]; Dino Amadori [1]; Wainer Zoli (corresponding author) [1]
Background
Nitric oxide-releasing non-steroidal anti-inflammatory drugs (NO-NSAIDS), which consist of a traditional NSAID linked to an -NO
2
moiety via a molecular spacer, represent a promising class of compounds. These drugs were developed to overcome gastrointestinal and renal toxicities, the main limitations in the long-term use of traditional NSAIDs as chemoprotective agents against colon cancer. The rationale behind NO-NSAID development was based on the ...
Related newspaper, magazine, and journal articles:
|
|
Article: PivX and NCX Group Partner to Reach Reseller Community; ...
Business Wire;
June 23, 2004 ;
700+ words
... ... has executed a strategic partnership with NCX Group, a leading business risk management consulting firm. Through this agreement, NCX Group will act as a market development partner ... Qwik-Fix Pro, is being marketed by NCX as NowSecure. NCX Group gives PivX significant ...
|
|